论文部分内容阅读
动物实验已表明bestatin既能加强体液免疫又能加强细胞免疫反应。每天给癌患者口服bestatin 30mg,血淋巴细胞计数无变化,但显著增加T-细胞在淋巴细胞中的比例,Fc-IgG受体阳性的淋巴细胞的比例趋向正常,具有C’3受体淋巴细胞的比例无变化。用同位素~(51)Cr标记Chang和K562靶细胞以检测药物对杀伤细胞活性的影响,证明bestatin可增加杀伤细胞活性,而不影响或仅轻度增加淋巴细胞对PHA和PPD的反应。该药对病人完全无毒性。外周淋巴细胞与bestatin一起培育可增加T细胞的比例,且似能阻止Fc-IgG受体在培育期间从淋巴细胞上脱落。淋巴细胞在体外与bestatin培育,杀伤细胞活性增加,但对抗体依赖和PHA依赖的细胞毒作用无影响。在体外bestatin又能抑制PWM诱导淋巴细胞合成的免疫球蛋白,但不影响其对淋巴细胞的转化作用。药物对实体瘤的治疗效果与病人的免疫状况密切有关。作者对bestatin的免疫恢复和促进作用进行了
Animal experiments have shown that bestatin enhances both humoral and cellular immune responses. Daily oral bestatin 30 mg for cancer patients, no change in blood lymphocyte count, but significant increase in the proportion of T-cells in lymphocytes, the proportion of Fc-IgG receptor-positive lymphocytes tends to normal, with C’3 receptor lymphocytes There is no change in the ratio. Isotope ~ (51) Cr was used to label Chang and K562 target cells to detect the effect of drugs on killer cell activity, demonstrating that bestatin can increase the activity of killer cells without affecting or only slightly increasing lymphocyte response to PHA and PPD. The drug is completely non-toxic to the patient. Incubation of peripheral lymphocytes with bestatin can increase the proportion of T cells and appears to prevent the Fc-IgG receptor from falling out of lymphocytes during incubation. Lymphocytes were incubated with bestatin in vitro and the killer cell activity was increased, but there was no effect on antibody-dependent and PHA-dependent cytotoxicity. Bestatin in vitro can inhibit the immunoglobulin of PWM-induced lymphocyte synthesis, but does not affect its conversion to lymphocytes. The therapeutic effect of drugs on solid tumors is closely related to the patient’s immune status. The author carried out the immunological recovery and promotion of bestatin